{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-325031","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2026-07-30T12:32:49+00:00","discovered_at":"2026-07-30T12:35:01.400311+00:00","generated_at":"2026-07-30T12:35:07.833402+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Disc Medicine aligns with FDA on bitopertin CRL path; APOLLO topline due Q4 2026","bullets":["FDA Type A meeting aligned that successful Phase 3 APOLLO can serve as basis for CRL response; topline data expected Q4 2026.","Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026; net loss of $59.5M in Q2 2026 vs $55.2M in Q2 2025.","RESTORE-PV Phase 2 of DISC-3405 fully enrolled; initial data now expected in Q3 2026.","Selcodebart RALLY-MF data showed 56% major anemia response rate; end-of-Phase 2 FDA meeting expected by year-end.","Expanded Access Program launched for bitopertin in EPP in the US and select geographies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-325031","json":"https://secwatch.observer/filing/0001193125-26-325031.json","markdown":"https://secwatch.observer/filing/0001193125-26-325031.md","text":"https://secwatch.observer/filing/0001193125-26-325031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/0001193125-26-325031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T12:35:07.833402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}